J&J Talc MDL: 69,000 Claims Ordered to Justify Specific Causation

A federal magistrate judge has ordered claimants across the Johnson & Johnson talcum powder litigation to show cause why their cases should not be dismissed, after plaintiffs' lead counsel withdrew both of their specific causation experts. The July 22, 2026 order from U.S. Magistrate Judge Rukhsanah Singh in the District of New Jersey reaches a docket that held 68,435 pending cases as of July 1, 2026 — making it one of the broadest causation challenges ever entered in an active mass tort.

Singh gave plaintiffs' lawyers until November 19 to respond, and U.S. District Judge Michael Shipp has set an August 3 hearing. The order does not dismiss anything on its own. Singh wrote that the "visceral reaction" to J&J's motion may be that it seeks instant dismissal of the entire MDL, but that she viewed it instead as an opportunity to assess "what claims may be meritorious and what claims may not."

What Triggered the Order

J&J filed its motion on June 11, 2026, after an evidentiary hearing in May in which the plaintiffs' two specific causation experts acknowledged that other risk factors could have contributed to the cancers of the six women selected as bellwether plaintiffs. Lead counsel then withdrew both experts. In J&J's framing, that withdrawal left plaintiffs "unable to satisfy an essential element of their claims," and the concessions elicited at the hearing showed the problem was not confined to six files. Coverage at the time called the sequence a stunning turn of events in a litigation that has been pending for more than a decade.

Plaintiffs argued that applying rulings about two bellwether experts to tens of thousands of other claimants would violate those claimants' due process rights. Singh rejected that, finding no due process concern had been shown, and calculated the affected population at closer to 69,000.

The litigation reached this point through an unusually turbulent stretch. A special master reviewing the expert record told Shipp that one key expert's "methodology lacks nearly all of the traditional indicia of reliability," according to Legal Newsline reporting. The Plaintiffs' Steering Committee is now led by Ashcraft & Gerel following the disqualification of Beasley Allen, which the New Jersey Appellate Division removed from 3,600 state court cases and which Singh removed from the federal MDL. Filings have continued regardless: more than 400 new talc cases entered the MDL in the weeks before July.

Why Specific Causation Turns on the Individual Chart

The distinction at the center of the order is one that shapes documentation requirements in every pharmaceutical and toxic tort docket. General causation is a question about a product and a population. Specific causation is a question about one person, and it is answered from that person's medical history.

Under New Jersey law, the differential diagnosis that supports a specific causation opinion is a two-step process: ruling in the plausible causes, then eliminating them. The state Supreme Court recently imposed gatekeeping standards at both steps. Singh found that one withdrawn expert never performed the second step at all, and that the other "could not justify his determinations as to whether to rule out a particular risk factor," per Legal Newsline.

That is where the order becomes a records problem rather than a purely scientific one. Ruling a risk factor out requires documentation of that risk factor — parity and gynecologic history, family cancer history and any genetic testing, body mass index over time, hormone therapy and contraceptive use, tumor subtype from pathology. An expert cannot eliminate what the chart never established.

What This Means for Talc Inventories

Firms holding talc claims now face a November deadline measured in evidentiary completeness rather than argument. A response that asserts a substantial-contributing-factor theory without per-claimant support invites the same critique the withdrawn experts drew.

The Record Audit Comes First

Any credible showing requires knowing, claimant by claimant, what the file actually contains: whether pathology identifies the tumor subtype, whether obstetric and gynecologic history is documented, whether family history and genetic testing results were ever obtained, and whether treating oncology notes describe the diagnostic workup. For inventories in the hundreds or thousands, that is a retrieval and review exercise, and one that AI-assisted services including LlamaLab are built to run at that scale. Firms that have never pulled complete charts on inventory claims — a common posture in dockets awaiting global settlement — have the furthest to travel by November 19.

Other Defendants Are Watching

The mechanism J&J used is portable. Any defendant in an aged MDL whose bellwether expert record weakens can point to that record and ask a court to require the remaining claimants to justify their causation proof. Singh's willingness to extend bellwether expert findings across a docket, over a due process objection, is the part of this order most likely to be cited elsewhere.

What Comes Next

The August 3 hearing before Shipp will indicate whether the bellwether program continues in its current form, and whether the court expects individualized submissions or a consolidated response from the steering committee. State court cases, concentrated in New Jersey and California, are unaffected by the federal order and continue on their own tracks. Verdicts there have been inconsistent — in Los Angeles, the first bellwether produced a $40 million plaintiff verdict and the second a defense verdict, according to Legal Newsline.

Worth noting what this order is not. It is not a dismissal, it is not a ruling that talc does not cause ovarian cancer, and it does not resolve the pending Rule 702 motions. It is a demand for case-specific proof, on a deadline.

The Bottom Line

The talc MDL has shifted from litigating whether talc can cause ovarian cancer to litigating whether any expert can say it caused a particular plaintiff's cancer. That question is answered from the chart, and the chart has to exist first.

Firms with talc inventory have roughly four months to know what is in each file. The claims most exposed are not the weakest on the merits — they are the ones where nobody has looked.

Sources: Law.com (July 22, 2026), Law.com (July 16, 2026), Legal Newsline via The Center Square, JPML Pending MDL Dockets, July 1, 2026, Drugwatch, USA Herald. Case counts current as of July 2026. This article is for informational purposes only and does not constitute legal or medical advice.